Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab
The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's sy...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2021/02/15, Vol.60(4), pp.639-643 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 643 |
|---|---|
| container_issue | 4 |
| container_start_page | 639 |
| container_title | Internal Medicine |
| container_volume | 60 |
| creator | Kataoka, Hiroshi Kodama, Fumihiro Tomita, Tomoko Kondo, Makoto Nagasaka, Atsushi Nishikawa, Shuji Mukai, Masaya |
| description | The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases. |
| doi_str_mv | 10.2169/internalmedicine.6010-20 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7946515</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2495030189</sourcerecordid><originalsourceid>FETCH-LOGICAL-c585t-fde684d1c1d3f5520dfa7d41cfce4550221ad7a9036d7a867a9572d93cb5b3023</originalsourceid><addsrcrecordid>eNptkU-O0zAUhyMEYjoDV0CWWMAmg__ESbxBGrUMVBpRiRa2luu8tK4cu9jJoHIIjsMFuBiOWioYsfGznj9_9tMvyxDB15SU4o1xPQSnbAeN0cbBdYkJzil-lE0IK0ReUcYfZxMsSJ3TtFxklzHuMGZ1JejT7IIxJnAh8CT7Me9GieoB3XRgjQ-qN94h36Il3EMA9Ani3qSuDwc0M7EPECMyDi13v35uArhXES0Prgm-A_TN9Fs0XXyZz3Ii0CpA8jbHrkJL4zYW0MxHGPWLts2tWoNFK6-NNd-HTq2fZU9aZSM8P9Wr7PPtu9X0Q363eD-f3tzlmte8z9sGyrpoiCYNazmnuGlV1RREtxoKzjGlRDWVEpiVqdRl2vKKNoLpNV8zTNlV9vbo3Q_rNL8G1wdl5T6YToWD9MrIf0-c2cqNv5eVKEpOeBK8PgmC_zpA7GVnogZrlQM_REmLimPBiWAJffkA3flhTG-kBMcMk1okqj5SOvgYA7TnzxAsx9Dlw9DlGLqkOF198fcw54t_Uk7AxyOwi73awBlQoTfawv_MshiX0wtnUG9VkODYbwoSzTY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2495030189</pqid></control><display><type>article</type><title>Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab</title><source>J-STAGE Free</source><source>MEDLINE</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Kataoka, Hiroshi ; Kodama, Fumihiro ; Tomita, Tomoko ; Kondo, Makoto ; Nagasaka, Atsushi ; Nishikawa, Shuji ; Mukai, Masaya</creator><creatorcontrib>Kataoka, Hiroshi ; Kodama, Fumihiro ; Tomita, Tomoko ; Kondo, Makoto ; Nagasaka, Atsushi ; Nishikawa, Shuji ; Mukai, Masaya</creatorcontrib><description>The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.6010-20</identifier><identifier>PMID: 33390490</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>acute respiratory distress syndrome ; Adrenal Cortex Hormones - therapeutic use ; Aged, 80 and over ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Autoimmune diseases ; Case Report ; Coronaviruses ; COVID-19 ; COVID-19 - complications ; COVID-19 - immunology ; Cytokine Release Syndrome ; cytokine storm ; Diabetes mellitus ; Drug Therapy, Combination ; Dyspnea - etiology ; Humans ; Internal medicine ; Male ; Off-Label Use ; Pandemics ; Public health ; Respiratory Distress Syndrome - drug therapy ; Respiratory Distress Syndrome - etiology ; Respiratory Insufficiency - drug therapy ; Risk factors ; SARS-CoV-2 ; Sjogren's syndrome ; Sjogren's Syndrome - complications ; Sjögren's syndrome ; Supplements ; tocilizumab</subject><ispartof>Internal Medicine, 2021/02/15, Vol.60(4), pp.639-643</ispartof><rights>2021 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2021</rights><rights>Copyright © 2021 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c585t-fde684d1c1d3f5520dfa7d41cfce4550221ad7a9036d7a867a9572d93cb5b3023</citedby><cites>FETCH-LOGICAL-c585t-fde684d1c1d3f5520dfa7d41cfce4550221ad7a9036d7a867a9572d93cb5b3023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946515/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946515/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1883,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33390490$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kataoka, Hiroshi</creatorcontrib><creatorcontrib>Kodama, Fumihiro</creatorcontrib><creatorcontrib>Tomita, Tomoko</creatorcontrib><creatorcontrib>Kondo, Makoto</creatorcontrib><creatorcontrib>Nagasaka, Atsushi</creatorcontrib><creatorcontrib>Nishikawa, Shuji</creatorcontrib><creatorcontrib>Mukai, Masaya</creatorcontrib><title>Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases.</description><subject>acute respiratory distress syndrome</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Aged, 80 and over</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Autoimmune diseases</subject><subject>Case Report</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - immunology</subject><subject>Cytokine Release Syndrome</subject><subject>cytokine storm</subject><subject>Diabetes mellitus</subject><subject>Drug Therapy, Combination</subject><subject>Dyspnea - etiology</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>Male</subject><subject>Off-Label Use</subject><subject>Pandemics</subject><subject>Public health</subject><subject>Respiratory Distress Syndrome - drug therapy</subject><subject>Respiratory Distress Syndrome - etiology</subject><subject>Respiratory Insufficiency - drug therapy</subject><subject>Risk factors</subject><subject>SARS-CoV-2</subject><subject>Sjogren's syndrome</subject><subject>Sjogren's Syndrome - complications</subject><subject>Sjögren's syndrome</subject><subject>Supplements</subject><subject>tocilizumab</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU-O0zAUhyMEYjoDV0CWWMAmg__ESbxBGrUMVBpRiRa2luu8tK4cu9jJoHIIjsMFuBiOWioYsfGznj9_9tMvyxDB15SU4o1xPQSnbAeN0cbBdYkJzil-lE0IK0ReUcYfZxMsSJ3TtFxklzHuMGZ1JejT7IIxJnAh8CT7Me9GieoB3XRgjQ-qN94h36Il3EMA9Ani3qSuDwc0M7EPECMyDi13v35uArhXES0Prgm-A_TN9Fs0XXyZz3Ii0CpA8jbHrkJL4zYW0MxHGPWLts2tWoNFK6-NNd-HTq2fZU9aZSM8P9Wr7PPtu9X0Q363eD-f3tzlmte8z9sGyrpoiCYNazmnuGlV1RREtxoKzjGlRDWVEpiVqdRl2vKKNoLpNV8zTNlV9vbo3Q_rNL8G1wdl5T6YToWD9MrIf0-c2cqNv5eVKEpOeBK8PgmC_zpA7GVnogZrlQM_REmLimPBiWAJffkA3flhTG-kBMcMk1okqj5SOvgYA7TnzxAsx9Dlw9DlGLqkOF198fcw54t_Uk7AxyOwi73awBlQoTfawv_MshiX0wtnUG9VkODYbwoSzTY</recordid><startdate>20210215</startdate><enddate>20210215</enddate><creator>Kataoka, Hiroshi</creator><creator>Kodama, Fumihiro</creator><creator>Tomita, Tomoko</creator><creator>Kondo, Makoto</creator><creator>Nagasaka, Atsushi</creator><creator>Nishikawa, Shuji</creator><creator>Mukai, Masaya</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210215</creationdate><title>Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab</title><author>Kataoka, Hiroshi ; Kodama, Fumihiro ; Tomita, Tomoko ; Kondo, Makoto ; Nagasaka, Atsushi ; Nishikawa, Shuji ; Mukai, Masaya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c585t-fde684d1c1d3f5520dfa7d41cfce4550221ad7a9036d7a867a9572d93cb5b3023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>acute respiratory distress syndrome</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Aged, 80 and over</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Autoimmune diseases</topic><topic>Case Report</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - immunology</topic><topic>Cytokine Release Syndrome</topic><topic>cytokine storm</topic><topic>Diabetes mellitus</topic><topic>Drug Therapy, Combination</topic><topic>Dyspnea - etiology</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>Male</topic><topic>Off-Label Use</topic><topic>Pandemics</topic><topic>Public health</topic><topic>Respiratory Distress Syndrome - drug therapy</topic><topic>Respiratory Distress Syndrome - etiology</topic><topic>Respiratory Insufficiency - drug therapy</topic><topic>Risk factors</topic><topic>SARS-CoV-2</topic><topic>Sjogren's syndrome</topic><topic>Sjogren's Syndrome - complications</topic><topic>Sjögren's syndrome</topic><topic>Supplements</topic><topic>tocilizumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kataoka, Hiroshi</creatorcontrib><creatorcontrib>Kodama, Fumihiro</creatorcontrib><creatorcontrib>Tomita, Tomoko</creatorcontrib><creatorcontrib>Kondo, Makoto</creatorcontrib><creatorcontrib>Nagasaka, Atsushi</creatorcontrib><creatorcontrib>Nishikawa, Shuji</creatorcontrib><creatorcontrib>Mukai, Masaya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kataoka, Hiroshi</au><au>Kodama, Fumihiro</au><au>Tomita, Tomoko</au><au>Kondo, Makoto</au><au>Nagasaka, Atsushi</au><au>Nishikawa, Shuji</au><au>Mukai, Masaya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2021-02-15</date><risdate>2021</risdate><volume>60</volume><issue>4</issue><spage>639</spage><epage>643</epage><pages>639-643</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>33390490</pmid><doi>10.2169/internalmedicine.6010-20</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2021/02/15, Vol.60(4), pp.639-643 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7946515 |
| source | J-STAGE Free; MEDLINE; PubMed Central Open Access; PubMed Central |
| subjects | acute respiratory distress syndrome Adrenal Cortex Hormones - therapeutic use Aged, 80 and over Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Autoimmune diseases Case Report Coronaviruses COVID-19 COVID-19 - complications COVID-19 - immunology Cytokine Release Syndrome cytokine storm Diabetes mellitus Drug Therapy, Combination Dyspnea - etiology Humans Internal medicine Male Off-Label Use Pandemics Public health Respiratory Distress Syndrome - drug therapy Respiratory Distress Syndrome - etiology Respiratory Insufficiency - drug therapy Risk factors SARS-CoV-2 Sjogren's syndrome Sjogren's Syndrome - complications Sjögren's syndrome Supplements tocilizumab |
| title | Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T14%3A33%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immediate%20Amelioration%20of%20Severe%20Respiratory%20Distress%20in%20Sj%C3%B6gren's%20Syndrome%20with%20COVID-19%20Treated%20with%20a%20Single%20Dose%20of%20Off-label%20Tocilizumab&rft.jtitle=Internal%20Medicine&rft.au=Kataoka,%20Hiroshi&rft.date=2021-02-15&rft.volume=60&rft.issue=4&rft.spage=639&rft.epage=643&rft.pages=639-643&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.6010-20&rft_dat=%3Cproquest_pubme%3E2495030189%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2495030189&rft_id=info:pmid/33390490&rfr_iscdi=true |